Deep Research Archives

The Global Burden of Alzheimer's Disease: Costs, Suffering, and Pathways to Solutions

1. Introduction: The Global Imperative of Addressing Alzheimer's Disease Alzheimer's disease (AD) represents a profound and escalating global health crisis, demanding urgent and comprehensive attention. It is a progressive neurodegenerative disorder, distinct from normal aging, characterized by the irreversible degeneration of brain cells. This degeneration leads to severe disruptions in memory, cognition, personality, and other critical functions necessary for daily life, ultimately culminating in complete brain failure and death.1 The worldwide prevalence of Alzheimer's and other dementias is staggering, with an estimated 55 million to 57 million people currently affected globally.1 This number is projected to surge dramatically, potentially exceeding 152 million by 2050 if significant breakthroughs in prevention or cure are not achieved.1 The rapid pace of new diagnoses underscores the urgency of this challenge, with approximately 10 million new cases of dementia emerging globally each year, equivalent to one new case every three seconds.1 As the most common form of dementia, Alzheimer's accounts for an estimated 60% to 70% of all cases.3 It is currently ranked as the seventh leading cause of death worldwide and stands as a primary driver of disability and dependency among older populations globally.3 The challenges presented by Alzheimer's disease are multifaceted, extending far beyond the individual patient. The condition creates profound physical, psychological, social, and economic burdens for caregivers, families, communities, and national economies.3 A significant obstacle to effective management and support is the pervasive lack of public awareness and understanding of dementia. This often results in stigmatization, creating substantial barriers to timely diagnosis and access to necessary care.3 The inherently progressive and debilitating nature of AD, coupled with a historical absence of effective disease-modifying treatments, has contributed to an enormous and growing economic and societal burden on healthcare systems and support infrastructures.5 While the reported numbers of people living with dementia are immense, a deeper examination reveals a critical, often unrecognized problem: the vast majority of cases remain undiagnosed, particularly in certain regions. Over 60% of dementia cases occur in low- and middle-income countries, and a staggering 75% of all dementia cases globally go undiagnosed, with this figure soaring to as high as 90% in some low-income nations.1 This widespread underdiagnosis means that millions of individuals are suffering without the necessary support, and societies are largely unprepared for the escalating demands. This situation effectively renders Alzheimer's a "silent epidemic," disproportionately affecting vulnerable populations and regions that may lack the resources or infrastructure to identify and address the disease adequately. Furthermore, the description of Alzheimer's as an irreversible degeneration leading to significant disability and dependency highlights a prolonged period of care needs for affected individuals.1 The fact that AD is the seventh leading cause of death and its increasing mortality rate signify not only individual tragedies but also a growing, long-term strain on national healthcare systems, social services, and the broader economy due to lost productivity and increased demand for care.1 This underscores that addressing Alzheimer's disease is not merely a medical challenge but a fundamental societal imperative that directly impacts economic stability and social cohesion across generations.
2. The Economic and Societal Burden of Alzheimer's The economic and societal burden of Alzheimer's disease is monumental, imposing significant costs on healthcare systems, families, and national economies worldwide. 2.1 Global Financial Costs The global economic impact of dementia was estimated at US1.3trillionin2019.[3]ThisfigureisprojectedtoescalatedramaticallytoUS2 trillion by 2030, representing more than 1% of the world's Gross Domestic Product (GDP).4 In high-income countries, the financial burden is distributed, with approximately 45% of costs attributed to informal (unpaid) care and 40% to formal social care systems.4 In the United States specifically, health and long-term care expenditures for individuals living with Alzheimer's and other dementias are projected to reach $384 billion in 2025.1 This is forecasted to rise to nearly $1 trillion by 2050, and these projections do not even include the substantial value of unpaid caregiving.5 Government programs bear a significant portion of these direct costs: Medicare and Medicaid are expected to cover $246 billion (64%) of the U.S. costs in 2025, while out-of-pocket spending by individuals and families is projected to be $97 billion.8 The financial strain on public healthcare systems is evident, as Medicare costs for individuals with dementia are three times higher, and Medicaid costs are 22 times higher, compared to older adults without dementia.8 Moreover, people with AD experience twice as many hospital stays per year and are more likely to suffer from other chronic conditions, such as heart disease, diabetes, and kidney disease, further increasing healthcare utilization and associated costs.8 2.2 The Profound Economic Value and Personal Cost of Unpaid Caregiving A significant portion of the global dementia cost, approximately 50%, is attributable to the invaluable care provided by informal caregivers—typically family members and close friends—who dedicate an average of five hours of care and supervision daily.3 This substantial contribution highlights a critical, often overlooked aspect of the disease's economic impact. In the United States alone, nearly 12 million Americans serve as unpaid caregivers for individuals with dementia.6 In 2024, the estimated value of these unpaid care hours exceeded 19 billion hours, totaling more than $413 billion.6 To contextualize this immense contribution, this value is nearly 16 times the total revenue of McDonald's in 2023.8 This demonstrates a colossal, yet often invisible, economic contribution that supports the formal healthcare system. Families are the primary financial shock absorbers, shouldering 70% of the total lifetime cost of caring for someone with dementia. This burden comes through a combination of out-of-pocket health and long-term care expenses and the immense value of their unpaid care.8 The estimated lifetime cost of dementia care, including unpaid caregiving, is nearly $395,000.9 Families typically spend over $10,000 annually in out-of-pocket health and long-term care costs for a senior with AD, which is more than four times the average for seniors without dementia.9 The financial burden intensifies significantly in the last five years of a person's life with dementia, with family out-of-pocket health care spending totaling nearly $87,000. This is more than twice the cost for cancer patients and approximately 75% higher than for heart disease patients.9 This level of spending can consume a third of a family's wealth, compared to just 11% for individuals with other conditions.9 Alarmingly, for Black families, dementia in the last five years of life can consume, on average, over 80% of their assets, underscoring severe health equity disparities and the disproportionate impact on certain communities.9 To cope with these overwhelming costs, many caregivers resort to drastic financial measures. Data indicates that 48% cut back on their own essential expenses, including food, transportation, and medical care, to pay for dementia-related care.9 Furthermore, 20% utilize their retirement savings, and 15% find it necessary to borrow money.9 Disturbingly, one in nine caregivers even reduce spending on their children's education.9 The economic consequences extend to employment: more than one in six Alzheimer's caregivers are forced to give up their jobs entirely, either to become a caregiver or because their duties become too burdensome.9 Among those who continue to work, 57% experience significant disruptions, such as arriving late, leaving early, or taking time off due to their caregiving responsibilities.9 This substantial loss of income can have severe and long-term financial repercussions for caregivers and their families.10 The absorption of a large percentage of Alzheimer's costs by families through unpaid caregiving represents a massive, often unacknowledged, transfer of economic burden from formal healthcare systems and public budgets onto individual households. This "hidden economy" of caregiving, valued at hundreds of billions of dollars annually in the U.S. alone, has profound ripple effects. It leads to families depleting retirement savings, incurring debt, and sacrificing their own well-being. This situation points to a systemic flaw where the most vulnerable are forced to bear the brunt of a societal challenge, emphasizing the urgent need for policy interventions that recognize and alleviate this immense familial financial strain. 2.3 Projections for Future Economic Impact The projected increases in global and national costs—to US$2 trillion globally by 2030 and nearly $1 trillion in the U.S. by 2050—indicate an unsustainable trajectory under current care models.4 This escalating financial burden threatens to overwhelm health and social services, including long-term care systems, globally.4 A critical workforce gap is anticipated in the U.S. direct care sector, with nearly 900,000 additional workers needed between 2022 and 2032 to care for the growing dementia population.8 This represents the largest worker gap of any single occupation in the U.S..8 The challenge is further exacerbated by high annual turnover rates, estimated at 80% for those providing home care and 99% for nursing assistants in nursing homes.8 This impending shortage and high turnover directly threaten the capacity to provide adequate care, potentially leading to crises in care quality and accessibility as the prevalence of Alzheimer's disease continues to rise. The ability to meet the growing demand for care is severely compromised by these workforce challenges, making it a critical area for immediate intervention.
3. The Human Toll: Suffering of Patients and Families Beyond the staggering economic figures, Alzheimer's disease exacts a profound human toll, inflicting immense emotional, psychological, and physical suffering on both patients and their families. 3.1 Emotional and Psychological Burden on Caregivers For many families, caring for a loved one with Alzheimer's is a profoundly overwhelming experience.10 More than half of caregivers report high or very high levels of emotional stress.9 This distress is often compounded by feelings of isolation, a sense of being misunderstood, and a lack of adequate support from others who may not fully comprehend the immense stress and challenges they face.10 This isolation can further exacerbate feelings of sadness and depression.10 A significant number of caregivers, approximately one-quarter, belong to the "sandwich generation," meaning they are simultaneously caring for an aging parent with dementia and at least one child, adding another layer of complex responsibilities and stress.8 The constant emotional and psychological demands, coupled with the isolation experienced by caregivers, often culminates in a phenomenon known as "caregiver burnout." This is a serious concern that manifests as overwhelming feelings of exhaustion, hopelessness, and frustration.10 When caregivers reach this state, it can unfortunately lead to a decrease in the quality of care provided to the person with Alzheimer's.10 This widespread and severe emotional and psychological toll on caregivers highlights a public health crisis in itself, demanding proactive support systems to prevent widespread physical and mental health deterioration among those providing essential care. 3.2 Physical Strain and Health Consequences for Caregivers Caregiving for someone with Alzheimer's is not only emotionally taxing but also physically demanding, leading to significant physical strain and adverse health consequences for caregivers. The tasks involved, such as helping with mobility, feeding, bathing, and dressing, are physically arduous.10 As a result, over one-third of caregivers report high or very high levels of physical stress 9, and they face an increased risk of developing their own health problems.10 Sleep deprivation is a common and debilitating issue for Alzheimer's caregivers, as individuals with the disease often experience disrupted sleep patterns, agitation, or frequent nighttime awakenings. This can leave caregivers awake during the night, unable to obtain sufficient rest.10 Chronic sleep deprivation severely impacts a caregiver's health, contributing to fatigue, mood swings, difficulty concentrating, and an increased risk of accidents.10 Alarmingly, more than one in three Alzheimer's caregivers report that their own health has worsened due to their care responsibilities, a figure significantly higher than the 19% reported by non-dementia caregivers.9 Furthermore, one in five care contributors reduce their own doctor visits, and one in nine do not always purchase necessary medications for themselves.9 A substantial 74% of caregivers express concern about maintaining their own health since assuming their caregiving role.9 3.3 Impact on Patient Quality of Life For individuals living with Alzheimer's disease, the irreversible degeneration of the brain progressively erodes their memory, cognition, personality, and ability to perform daily functions.1 This profound loss of capabilities, combined with the pervasive societal stigma surrounding dementia and a lack of public understanding, often creates significant barriers to receiving a timely diagnosis and accessing appropriate care.3 This loss of function, coupled with societal attitudes, can lead to social exclusion and a diminished sense of dignity for patients.3 As the disease advances, individuals become increasingly dependent, impacting their autonomy and ability to live a life with meaning and dignity.4 This emphasizes that effective Alzheimer's management must extend beyond purely medical treatment to include strategies that actively preserve patient autonomy, foster social connection, and enhance overall quality of life, highlighting the crucial need for a "dementia-friendly society" that supports and includes those affected.
4. Current Treatments and the Research Landscape The landscape of Alzheimer's disease treatment is evolving, encompassing both symptomatic management and a growing focus on disease modification, alongside the critical role of non-pharmacological interventions and a robust research pipeline. 4.1 Approved Pharmacological Treatments and Their Mechanisms Current pharmacological treatments for Alzheimer's disease can be broadly categorized into those that treat cognitive symptoms, those that modify disease progression, and those that manage non-cognitive (behavioral and psychological) symptoms. Treatments for Cognitive Symptoms (Memory and Thinking): ⦁ Cholinesterase Inhibitors: Medications such as Donepezil (Aricept®), Galantamine (Razadyne®), Rivastigmine (Exelon®), and Benzgalantamine (Zunveyl®) are prescribed to address symptoms related to memory, thinking, language, and judgment. They function by preventing the breakdown of acetylcholine, a crucial chemical messenger for memory and learning, thereby supporting communication between nerve cells. These drugs are approved for mild-to-severe Alzheimer's disease, though specific indications vary (e.g., Benzgalantamine for mild-to-moderate). Common side effects include nausea, vomiting, diarrhea, dizziness, headache, loss of appetite, muscle cramps, and increased frequency of bowel movements.11 ⦁ Glutamate Regulator: Memantine (Namenda®) is approved for moderate-to-severe Alzheimer's disease. It works by regulating glutamate, another important brain chemical. Potential side effects include headache, constipation, confusion, and dizziness.11 ⦁ Combination Therapy: Namzaric®, a combination of Donepezil and Memantine, is approved for moderate-to-severe Alzheimer's disease, with side effects similar to its individual components.11 Disease-Modifying Treatments (DMTs):
   A significant breakthrough in recent years has been the approval of monoclonal antibodies that directly target the underlying pathology of Alzheimer's. ⦁ Lecanemab (Leqembi®) and Donanemab (Kisunla™): These drugs target and remove amyloid-beta plaques, sticky protein deposits that build up in the brains of people with Alzheimer's disease and are thought to influence disease progression.12 Approved for early Alzheimer's (mild cognitive impairment or mild dementia), clinical trials have shown they can slow disease progression on composite scores by approximately 25-40%.13 Donanemab, for instance, has been reported to slow progression by about one-third, enabling patients to retain more of their typical daily activities, such as driving, engaging in hobbies, and discussing current events.12 ⦁ Limitations of DMTs: While promising, these treatments come with significant considerations. A notable side effect is Amyloid-Related Imaging Abnormalities (ARIA), which can involve bleeding and swelling in the brain. Although often asymptomatic, ARIA can, in rare cases, lead to serious or life-threatening events.15 Other common side effects include infusion-related reactions and headache.11 Questions have also been raised regarding the clinical meaningfulness of the observed modest benefits, and whether the efficacy truly outweighs the risks of ARIA.15 Furthermore, these drugs are currently expensive, costing around $27,000 to $34,000 per patient annually, and their availability can be limited in some healthcare systems (e.g., the UK's National Health Service has not yet offered them to patients).13 Treatments for Non-Cognitive Symptoms (Behavioral and Psychological): ⦁ Brexpiprazole (Rexulti®): This drug is approved for the treatment of agitation associated with dementia due to Alzheimer's disease. While its exact mechanism is unclear, it is thought to regulate neurotransmitters like dopamine and serotonin. It carries a black box warning from the FDA due to an increased risk of death in older adults with dementia-related psychosis.11 ⦁ Suvorexant (Belsomra®): Approved for insomnia, it has shown effectiveness in people with mild to moderate Alzheimer's disease. Potential side effects include impaired alertness and motor coordination, worsening of depression or suicidal thinking, complex sleep behaviors, sleep paralysis, and compromised respiratory function.11 4.2 Non-Pharmacological Interventions and Their Benefits Non-pharmacological interventions play an indispensable role in managing dementia, focusing on improving the quality of life for both patients and their families, and supporting cognitive and emotional well-being. Cognitive and Emotional Support: ⦁ Memory and Orientation Exercises: These include activities like arithmetic problems, number sequence completion, remembering and recognizing images, and puzzles. Interventions also involve practicing everyday tasks such as shopping.16 ⦁ Reality Orientation Training: This approach aims to improve a person's orientation in space and time by repeatedly providing basic information (name, date, time) through conversations or orientation aids like large calendars and room signs.16 ⦁ Reminiscence Therapy: Encouraging individuals with Alzheimer's to discuss past topics like their hometown, school days, or work can improve mental abilities, enhance quality of life, and alleviate psychological effects such as depression.16 ⦁ Therapies: Art therapy, aromatherapy, music therapy, and contact with animals have been shown to support patients' cognitive functions and offer potential benefits in improving quality of life.16 Physical Activity: ⦁ Exercise programs, including walking, strength-building exercises, and endurance exercises, typically involve two to three sessions per week, lasting 30 to 60 minutes each. These activities can help delay or slow a decline in thinking skills, reduce stress, potentially improve symptoms of depression, and reduce the risk of falls.16 Exercise is also believed to directly benefit brain cells by increasing blood and oxygen flow.18 Such programs help individuals with Alzheimer's maintain mobility and a sense of independence for longer periods.16 Social Engagement & Lifestyle: ⦁ Social Activities: Engaging in activities like discussion groups or preparing meals together can improve the quality of life for both people with Alzheimer's and their family members, help prevent Alzheimer's-related apathy, and potentially reduce the amount of care needed.16 ⦁ Healthy Diet: Some experts believe that adopting a healthy diet, particularly a Mediterranean diet, can help prevent or slow the progression of Alzheimer's and positively affect memory and cognitive abilities.16 ⦁ Mental Stimulation: Learning new information, taking a class, or challenging oneself with a new hobby or activity may help increase brain activity.18 Caregiver-Focused Interventions: ⦁ Caregiver Training Programs: These programs teach special communication techniques, emphasizing the creation of an atmosphere of closeness and care, and encouraging caregivers to accept the behavior and feelings of the person with Alzheimer's without judgment. Such training can enable individuals with Alzheimer's to live at home for a longer time.16 ⦁ Occupational Therapy: Occupational therapists help people with Alzheimer's maintain independence in everyday abilities like getting dressed and performing housework. They offer exercises, provide advice, and suggest adjustments to daily life, including concentration and memory training.16 4.3 The Drug Development Pipeline: Promising Avenues and Challenges The Alzheimer's drug development pipeline shows promising growth and diversification, reflecting a dynamic research environment. In 2025, there are 138 drugs being tested across 182 clinical trials, marking an increase in all phases compared to 2024.19 A significant 74% of these drugs are disease-targeted therapies (DTTs), aiming to slow or halt disease progression.19 Shifting Paradigms in Drug Development: The evolution from purely symptomatic treatments (like cholinesterase inhibitors and memantine) to disease-modifying therapies (DMTs) targeting amyloid represents a significant advancement.11 The approval of DMTs such as Lecanemab and Donanemab marks a vital first step in slowing disease progression.13 This shift is further evidenced by the pipeline's diversity, with 138 drugs in 182 trials, focusing on multiple targets beyond amyloid, including tau, inflammation, synaptic function, the gut-brain axis, and circadian rhythm disruptions.14 This multi-target approach acknowledges the complex pathology of Alzheimer's disease, moving beyond a singular focus and leveraging various biological pathways for potential therapeutic benefit. Diversified Approaches and Repurposing: A notable trend is the repurposing of existing drugs, with 33% of the drugs in the pipeline originally developed for other conditions.19 For instance, research into drugs like semaglutide, initially used for diabetes, showed a reduced risk of dementia, leading to clinical trials to test its potential in treating Alzheimer's.21 Results from some semaglutide trials are expected by September 2025.21 Additionally, cancer drugs have shown promise in reducing Alzheimer's risk and even reversing symptoms in mice, highlighting the potential for unexpected therapeutic avenues.22 Tau-Targeting Therapies: Following the breakthroughs in amyloid-targeting drugs, there is increasing focus on therapies that target tau protein, another hallmark of Alzheimer's. Drugs like BIIB080, which switches off tau production, are currently in trials and show promise in slowing or potentially reversing cognitive decline.14 Furthermore, novel vaccine approaches, such as a vaccine engineered to clear pathological tau protein, are in early-stage clinical trials (Phase 1a/1b), primarily assessing safety, tolerability, and immunogenicity.23 Other Innovations and Biomarkers: Research is also exploring other innovative non-drug methods, such as deep-brain stimulation, which in early stages has shown potential in mice by helping new nerve cells form through light pulses.14 Ultra-thin graphene implants are also under development.13 Biomarkers play a central role in current trials, used as inclusion criteria in over half of studies and as primary outcomes in 27%, with plasma-based p-tau217 gaining prominence for screening and monitoring treatment response.19 The Critical Role of Early Intervention and Diagnosis: The efficacy of disease-modifying treatments is often observed in individuals with "early Alzheimer's (MCI or mild dementia)".11 Some research suggests that these drugs could slow disease progression by as much as 60% if administered at an early stage.13 This strong emphasis on early intervention underscores the critical importance of early diagnosis. Currently, a major global challenge is the significant underdiagnosis of dementia, with 75% of cases going undiagnosed globally, exacerbated by stigma.1 This highlights that advancements in treatment effectiveness are intrinsically linked to improved diagnostic capabilities and widespread public awareness campaigns that encourage early detection. These non-pharmacological efforts are therefore crucial for maximizing the impact of new therapies. Challenges in Development: Despite the promising pipeline, significant challenges persist. Recruitment remains a major hurdle, with over 50,000 participants needed for current trials.19 Most trial sites host only a single trial, indicating a need for expanded and consolidated global recruitment efforts to improve efficiency and representation.19 Furthermore, the high cost of new drugs (e.g., $27,000-$34,000 per year) and the potential for serious side effects like ARIA continue to be barriers to widespread access and implementation.13
5. Global Strategies and Policy Recommendations Addressing the global challenge of Alzheimer's disease requires a concerted, multi-faceted approach involving international collaboration, robust policy frameworks, and a shift in public health strategies. 5.1 International Initiatives and Frameworks Several international bodies and national governments have recognized the escalating crisis of dementia and have initiated plans to combat it. ⦁ WHO Global Action Plan on the Public Health Response to Dementia (2017-2025): This comprehensive plan aims to improve the lives of people with dementia, their families, and caregivers, while simultaneously decreasing the impact of dementia on communities and countries.4 Its seven key action areas include raising awareness, reducing risk, improving diagnosis/treatment/care, supporting carers, enhancing information systems, and fostering research and innovation.4 By 2025, the plan targeted that 75% of countries would provide training and support for carers and implement public awareness campaigns.24 Recognizing the increasing prevalence and economic impact, the 78th World Health Assembly recently agreed to extend this Global Action Plan to 2031, signaling a sustained commitment to global action.2 ⦁ WHO Tools and Guidelines: The WHO has developed practical tools to support these efforts, including iSupport, an online training manual for dementia caregivers, and the Global Dementia Observatory (GDO), a platform for tracking and sharing data on dementia policies, services, and research.24 They also provide risk reduction guidelines, emphasizing physical activity, healthy eating, and managing medical conditions to lower dementia risk.24 The Mental Health Gap Action Programme (mhGAP) is designed to help healthcare providers, particularly in low- and middle-income countries, offer basic care for mental health disorders, including those related to the brain.24 ⦁ National Dementia Plans (NDPs): The WHO strongly encourages all countries to develop National Dementia Plans to localize and implement the global targets.24 ⦁ U.S. National Plan to Address Alzheimer's Disease (since 2012): The United States has its own comprehensive plan with ambitious goals, including preventing and effectively treating Alzheimer's and related dementias by 2025. Other objectives include enhancing care quality and efficiency, expanding support for patients and their families, improving public awareness and engagement, strengthening data collection, and accelerating efforts to promote healthy aging and reduce risk factors.25 This plan is coordinated across multiple federal agencies, including the Department of Health and Human Services (HHS), Department of Veterans Affairs (VA), National Science Foundation (NSF), and Department of Defense (DoD).25 The WHO Global Action Plan and national plans like the U.S. National Plan serve as crucial frameworks for addressing Alzheimer's. Fragmented approaches are insufficient; comprehensive strategies must connect research, early diagnosis, caregiver support, public awareness, and workforce development. This suggests that an effective global response requires not just medical breakthroughs but a coordinated, multi-sectoral commitment from governments, healthcare providers, and communities to transform societal infrastructure and attitudes towards dementia. 5.2 Policy Recommendations for Comprehensive Solutions To effectively address the multifaceted challenges posed by Alzheimer's disease, a range of integrated policy interventions are essential: ⦁ Sustained Investment in Research and Development: Continued and increased funding is critical for accelerating the development of diverse drug treatments, including disease-modifying therapies, repurposed drugs, and innovative non-pharmacological interventions. This investment should support both basic science and clinical trials across all phases.14 ⦁ Prioritizing Early Diagnosis and Equitable Access to Care: National strategies must be implemented to improve early diagnosis rates, reduce the pervasive stigma associated with dementia, and ensure equitable access to new treatments. This includes addressing the high costs and potential side effects of novel therapies to make them accessible to all who could benefit.1 ⦁ Robust Support Systems for Caregivers: Governments and healthcare systems must develop comprehensive support systems for unpaid caregivers. This includes providing financial assistance, expanding access to respite care, offering specialized training programs, and ensuring access to mental and physical health resources for caregivers. Recognizing and valuing their immense economic contribution is a crucial first step.8 ⦁ Widespread Public Awareness and Education Campaigns: Launching and sustaining broad public awareness campaigns is vital to increase understanding of Alzheimer's disease, challenge stigma, and promote brain health and risk reduction strategies across the lifespan.3 ⦁ Strategic Workforce Development: Addressing the critical shortage of direct care workers and geriatricians is paramount. This requires targeted recruitment efforts, comprehensive training programs, and initiatives to improve working conditions and retention rates within the care sector.8 ⦁ Integrated Patient-Centered Care Models: Promoting holistic care pathways that seamlessly integrate medical, social, and psychological support services for both patients and their families is essential. Such models ensure continuity of care and address the diverse needs arising from the disease.16 ⦁ Fostering Dementia-Friendly Societies: Initiatives to create environments where people living with dementia and their caregivers can remain included, active, and respected members of society are crucial. This involves community-level programs and public education to build empathy and support.24 A significant shift in approach is needed, moving from solely managing the illness to proactive public health prevention. The WHO's "risk reduction guidelines," which emphasize physical activity, healthy eating, and managing medical conditions, align with research indicating that up to 45% of dementia cases could potentially be delayed or reduced by addressing modifiable risk factors.24 This means that substantial progress can be made not just through new drugs, but by empowering individuals and communities to adopt healthier lifestyles and manage chronic conditions, thereby reducing the overall incidence and burden of Alzheimer's disease.
6. Conclusion Alzheimer's disease presents a rapidly escalating global health crisis with immense and growing economic and human costs. The disease's profound impact extends far beyond the individual patient, placing an unsustainable burden on families, healthcare systems, and national economies. The vast number of undiagnosed cases, particularly in low- and middle-income countries, signifies a silent epidemic that demands immediate global attention and resource allocation. The escalating financial strain, largely absorbed by families through invaluable but unpaid caregiving, coupled with an impending critical shortage of direct care workers, underscores the urgency of systemic change. While the human toll on patients involves a progressive loss of cognitive function and dignity, caregivers endure significant emotional, psychological, and physical suffering, often leading to burnout and compromised personal health. These intertwined challenges necessitate a multi-pronged approach that integrates medical advancements with robust social and policy interventions. Recent breakthroughs in pharmacological treatments, particularly disease-modifying therapies targeting amyloid, offer a vital first step in slowing disease progression, especially when administered early. The diverse and growing drug development pipeline, exploring multiple biological targets and repurposing existing medications, signals cautious optimism for future therapeutic options. However, the high cost and potential side effects of these new drugs highlight the ongoing challenge of equitable access. Crucially, non-pharmacological interventions, including cognitive exercises, physical activity, social engagement, and comprehensive caregiver support programs, remain indispensable for enhancing the quality of life for both patients and their families. Ultimately, addressing Alzheimer's disease effectively requires a global commitment to robust policy frameworks. This includes sustained investment in diverse research and development, national strategies to improve early diagnosis and ensure equitable access to care, comprehensive support systems for unpaid caregivers, widespread public awareness and education campaigns, strategic workforce development, and the promotion of integrated, patient-centered care models. By shifting towards a proactive public health approach that emphasizes risk reduction and fosters dementia-friendly societies, it is possible to mitigate the devastating impact of this disease and improve outcomes for millions worldwide through sustained, collaborative global efforts. 참고 자료
7. Alzheimer's Disease: Facts & Figures - BrightFocus Foundation, 7월 22, 2025에 액세스, https://www.brightfocus.org/alzheimers/facts-figures/
8. The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia | Alzheimer's Disease International (ADI), 7월 22, 2025에 액세스, https://www.alzint.org/news-events/news/the-78th-world-health-assembly-agrees-to-extend-the-global-action-plan-on-the-public-health-response-to-dementia/
9. Dementia - World Health Organization (WHO), 7월 22, 2025에 액세스, https://www.who.int/news-room/fact-sheets/detail/dementia
10. Global action plan on the public health response to dementia - IRIS, 7월 22, 2025에 액세스, https://iris.who.int/bitstream/handle/10665/259615/9789241513487-eng.pdf?sequence=1
11. The economic and societal burden of Alzheimer disease: managed care considerations - PubMed, 7월 22, 2025에 액세스, https://pubmed.ncbi.nlm.nih.gov/36197132/
12. 7 MILLION - Alzheimer's Association, 7월 22, 2025에 액세스, https://www.alz.org/getmedia/b4c15a1b-2f84-473b-a19c-0ee261a384e6/alzheimers-facts-and-figures-infographic.pdf
13. Worldwide cost of Alzheimer's more than 1% of world's GDP - HelpAge International, 7월 22, 2025에 액세스, https://www.helpage.org/news/worldwide-cost-of-alzheimers-more-than-1-of-worlds-gdp/
14. Alzheimer's Disease Facts and Figures, 7월 22, 2025에 액세스, https://www.alz.org/alzheimers-dementia/facts-figures
15. The Impact of Alzheimer's on Families, 7월 22, 2025에 액세스, https://portal.alzimpact.org/media/serve/id/5d77f273d5fc1
16. How Alzheimer's Impacts Family Caregivers Support | Senior Living Community, 7월 22, 2025에 액세스, https://bonaventuresenior.com/how-alzheimers-impacts-family-caregivers/
17. Medications for Memory, Cognition & Dementia-Related Behaviors | alz.org, 7월 22, 2025에 액세스, https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory
18. New Alzheimer's Disease Drugs Receive FDA Approval, Offering Hope - Baystate Health, 7월 22, 2025에 액세스, https://www.baystatehealth.org/articles/new-alzheimers-disease-drugs
19. 8 recent breakthroughs in the fight against Alzheimer's disease, 7월 22, 2025에 액세스, https://www.weforum.org/stories/2025/06/recent-breakthroughs-fight-against-alzheimers-disease/
20. Beyond lecanemab: unravelling the future of Alzheimer's treatments, 7월 22, 2025에 액세스, https://www.alzheimersresearchuk.org/news/beyond-lecanemab-unravelling-the-future-of-alzheimers-treatments/
21. Evaluating clinical meaningfulness of anti-β-amyloid therapies amidst amyloid-related imaging abnormalities concern in Alzheimer's disease | Brain Communications | Oxford Academic, 7월 22, 2025에 액세스, https://academic.oup.com/braincomms/article/6/6/fcae435/7915707
22. Alzheimer's disease: Learn More – Non-drug interventions for Alzheimer's disease - NCBI, 7월 22, 2025에 액세스, https://www.ncbi.nlm.nih.gov/books/NBK279355/
23. (PDF) The impact of non-pharmacological interventions on quality of life in dementia: a review of evidence and outcomes - ResearchGate, 7월 22, 2025에 액세스, https://www.researchgate.net/publication/387478371_The_impact_of_non-pharmacological_interventions_on_quality_of_life_in_dementia_a_review_of_evidence_and_outcomes
24. Taking Care of Yourself | Alzheimer's Association, 7월 22, 2025에 액세스, https://www.alz.org/help-support/i-have-alz/live-well/taking-care-of-yourself
25. 2025 Alzheimer's Drug Pipeline Shows Growth and Diversity - DEMENTIA RESEARCHER, 7월 22, 2025에 액세스, https://www.dementiaresearcher.nihr.ac.uk/2025-alzheimers-drug-pipeline-shows-growth-and-diversity/
26. AlzPipeline, 7월 22, 2025에 액세스, https://alzpipeline.com/
27. Researching new drugs for Alzheimer's disease, 7월 22, 2025에 액세스, https://www.alzheimers.org.uk/research/our-research/dementia-research-news/researching-new-drugs-alzheimers-disease
28. Can cancer drugs treat Alzheimer’s? New study thinks so, 7월 22, 2025에 액세스, https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/can-cancer-drugs-treat-alzheimers-new-study-thinks-so/articleshow/122828350.cms
29. UNM Researchers Receive Funding to Launch Clinical Trial of a New Alzheimer's Vaccine, 7월 22, 2025에 액세스, https://hscnews.unm.edu/news/unm-researchers-plan-clinical-trials-to-test-vaccine-against-alzheimers-promoting-tau-protein-6911889
30. WHO Global Action Plan on dementia | Alzheimer's Disease International (ADI), 7월 22, 2025에 액세스, https://www.alzint.org/what-we-do/partnerships/world-health-organization/who-global-plan-on-dementia/
31. Federal Commitment to Addressing Alzheimer's and Related Dementias, 7월 22, 2025에 액세스, https://www.alzheimers.gov/taking-action/federal-response
32. Home | Alzheimer's Disease International (ADI), 7월 22, 2025에 액세스, https://www.alzint.org/
33. Tips for Caregivers and Families of People With Dementia - Alzheimers.gov, 7월 22, 2025에 액세스, https://www.alzheimers.gov/life-with-dementia/tips-caregivers